Startups channel feed – Endpoints News

Startups channel feed

OrbiMed-backed Prelude Therapeutics raises $60M to tackle resistance to cancer treatments

6 years ago

Sticking to hottest trends in biopharma, Oncologie gathers $80M for next leg of trans-Pacific clinical journey

6 years ago

Artizan completes microbiome starter package with Brii deal, CSO hire and some money to dash for the clinic

6 years ago

Third Rock raises a record $770M to back its own brand of biotech startups — while 1 key partner exits

6 years ago

A new interleukin target for NASH spawns Singaporean biotech steered by well known players

7 years ago

Ed Kaye is taking his fledgling biotech to Wall Street, looking for a new injection of cash

7 years ago

Hercules vet launches a new life sciences lender with $400M to put into play

7 years ago

Some of the best connected players in the San Diego hub organize launch round for another biotech with an eye on trial data

7 years ago

As UK biotech gains steam, Syncona launches new Treg player while Cambridge spinout expands Series A

7 years ago

$1.3B Keytruda windfall will be used to accelerate translational drug R&D in the UK

7 years ago

They got bounced out of Alexion. Now David Hallal and Vikas Sinha are back with $150M and a focus on cell and gene therapies

7 years ago

A newly formed biotech launched out of George Daley’s Harvard lab adds global players to its syndicate, bringing its haul to $83M

7 years ago

One of the world's top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field

7 years ago

Roche spins out Nimble Therapeutics to capitalize on peptide drug discovery, with $10M support from Telegraph Hill Partners

7 years ago

Vowing to spark a revolution in small molecule R&D, Vividion equips itself with an extra $82M for the final stretch to the clinic

7 years ago

A biotech fledgling cross-bred in France and Switzerland launches to take on liver problems of global dimensions

7 years ago

GSK punts a failed cardio drug to a biotech startup — which has a new development strategy in mind

7 years ago

Serial biotech entrepreneur Michael Gilman takes his key to the $100M-plus club and goes all-in on drugging RNA

7 years ago

On a mission to make organ transplants safer and more durable, Blackstone gifts Talaris a new CEO, leads $100M round

7 years ago

Biotech startup grabs $27M launch round to pursue an R&D path blazed at Harvard and Boston Children’s

7 years ago

Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic development

7 years ago

Flagship unveils gut-focused upstart Kintai, with former GSK exec as chief

7 years ago

Alnylam spotlights just how good the efficacy data are for givosiran — tamping down on safety concerns

7 years ago

Sonde wants to listen for disease — M Ventures heard the Boston biotech, and led a $16M round to supercharge research

7 years ago

First page Previous page 58 59 606162 63 64 Next page Last page